Helix BioPharma Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Mehrling
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 401 Bay Street Toronto ON Canada M5H 2Y4
- IPO Date
- Nov 27, 2009
- Website
- helixbiopharma.com
- Similar Companies
- Business
- Helix BioPharma Corp. is a clinical-stage immuno-oncology company that develops novel therapies targeting hard-to-treat cancers, including non-small cell lung cancer, pancreatic, colon, ovarian cancers, and leukemia relapse post-stem cell transplantation. Founded in 1995 and headquartered in Vancouver, Canada, the company operates primarily in Canada, Switzerland, and collaborates with research institutions in the United States and Europe such as Moffitt Cancer Center and University Hospital Tuebingen. Its proprietary DOS47 technology platform powers a pipeline of bio-conjugates and antibody-enzyme conjugates that target CEACAM6-expressing tumors and modify the tumor microenvironment to enhance immune responses and synergize with checkpoint inhibitors. Core products and services include its flagship L-DOS47 (Tumour Defence Breaker), a clinical-stage antibody-enzyme conjugate in trials for solid tumors that neutralizes tumor acidity to activate anti-tumor immunity; LDOS001, LDOS002, LDOS003, and LDOS006, all advancing in phase I/II trials for non-small cell lung cancer and pancreatic cancer; V-DOS47, targeting vascular endothelial growth factor 2 receptor; LEUMUNA (LR 09, ulodesine hemiglutarate), a pre-IND oral immune checkpoint modulator for leukemia relapse after allogeneic stem cell transplantation with US FDA Orphan Drug Designation and patent protection to 2041; and GEMCEDA, a pre-IND oral gemcitabine prodrug combined with cedazuridine achieving 90% bioavailability for improved chemotherapy delivery in various cancers, patented to 2043. In 2025, Helix closed acquisitions of substantially all assets from Laevoroc Immunology AG and Laevoroc Chemotherapy AG, originally agreed in late 2024 and amended in December 2024 to issue 21 million common shares, securing intellectual property, inventory, and rights to LEUMUNA and GEMCEDA to expand its immune-oncology and chemotherapy portfolio. Also in May 2025, the company signed an agreement with Kerentech Consulting Ltd. to support ongoing fundraising efforts. These strategic moves strengthen its clinical-stage pipeline and position it for accelerated development amid a focus on first-in-class oncology medicines.
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Helix BioPharma Responds to Market Activity
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM
Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting
Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group